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ABSTRACT    
 
Background. The EU LeukoTreat program aims to connect, enlarge and improve existing 
national databases for leukodystrophies (LDs) and other genetic diseases affecting the white 
matter of the brain. Ethical issues have been placed high on the agenda by pairing the 
participating LD expert research teams with experts in medical ethics and LD patient families 
and associations. The overarching goal is to apply core ethics principles to specific project 
needs and ensure patient rights and protection in research addressing the context of these rare 
diseases.  
Aim. This paper looks at how ethical issues were identified and handled at project 
management level when setting up an ethics committee.  
Methods. Through a work performed as a co-construction between health professionals, ethics 
experts, and patient representatives, we expose the major ethical issues identified.  
Results. The committee acts as the forum for tackling specific issues tied to datasharing and 
patient participation: the thin line between care and research, the need for a charter 
establishing the commitments binding health professionals and the information items to be 
delivered. Ongoing feedback on the database, including delivering global results in a broad 
audience format, emerged as a key recommendation. Information should be available to all 
patients in the partner countries developing the database and should be scaled to different 
patient profiles.  
Conclusion. This work led to a number of recommendations for ensuring transparency and 
optimizing the partnership between scientists and patients. 
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MAIN TEXT  
Patient registries and databases are key tools for the development of biomedical and clinical 
research ― particularly in the field of rare diseases which faces specific challenges tied to 
small patient populations and variations among disease sub-types. Gathering information on a 
large scale has considerable potential for helping to improve diagnosis and treatment, promote 
the development of clinical trials, and facilitate recruitment,[1, 2]. 
One aim of the EU LeukoTreat program (www.leukotreat.eu) is to develop a supranational 
database geared specifically to leukodystrophy (LD) ― the LeukoDataBase (LeukoDB). 
Collecting clinical data on LD patients will improve understanding of the natural history, 
epidemiology and genotype–phenotype correlations of these disorders. The challenge is to 
connect, enlarge and improve pan-European databases on LDs and other genetic diseases 
affecting the white matter of the brain. Addressing this challenge entails organizing the 
collection and management of clinical and biological data, including genetic information. The 
objective is to foster the emergence of innovative therapeutic strategies as part of translational 
research designed to accelerate the clinical application of fundamental research results.  
LDs are a group of rare genetically inherited neurodegenerative diseases of the white matter 
and its main component, myelin. LDs predominantly affect young children but can also hit 
adults, causing cognitive deficits and potential loss of autonomy. The overall prevalence of 
LDs is approximately 1 in 10,000 of the population, with around 1,000 new cases every year 
in Europe. Despite great strides forward made over the past decade in terms of advance in 
each individual LD, there is currently still no curative therapy (see,[3,4] for review).  
LeukoTreat has placed ethics issues high up the agenda by pairing the participating LD expert 
research teams with experts in medical ethics and LD patient families and associations. The 
overarching goal is to apply core ethics principles to specific project needs and ensure patient 
rights and protection in research addressing the context of these rare diseases. The ethical 
approach was integrated right from the project’s outset to handle the sharing of medical 
information at a European level in the context of LD patients, which are a heterogeneous 
population characterized by variable clinical expression and age of appearance. This approach 
also considers the harmonization of information and consent on existing practices in national 
databases.  
This paper looks at how ethical issues were identified and handled at project management 
level during the project lifetime.  
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SYNERGY BETWEEN AN ETHICS COMMITTEE AND AN ETHICS RESEARCH 
GROUP 
Before starting LeukoTreat, the proposal first received approval from the EC ethics review 
board, which is an integral component of the research evaluation procedure under FP7,[5]. 
The EU report singled out the plan to form a project-long ethics committee as a positive. 
Indeed, a stand-out feature of LeukoTreat was that it attached a LeukoTreat Ethics Committee 
(LEC) to the ethics research group involved in the project.  
The LEC is composed of two categories of members:  project members (clinicians and the 
ethics research group) and independent non-project members, including international experts 
in medical ethics, human sciences and law professionals as well as representatives of patient 
organizations. The LEC was put together in accordance with EU recommendations for ethics 
review panels,[5]. The LEC is dedicated to the LeukoTreat project and is thus a separate 
entity to Institutional Review Boards (IRB) or Research Ethics Committees (REC) whose role 
is to review research proposals involving humans. The LEC is responsible for the ethical 
management and follow-up of the project during its lifetime. Its role is to help identify 
specific issues and facilitate discussion and awareness among project partners, especially 
those involved both in care and research. The LEC is a forum for discussion and debate: one 
of its main objectives is to offer guidance to LeukoTreat partners on the issues addressed in 
the project and on other issues that the Committee may identify over the course of the project. 
One of the LEC’s first tasks was to produce recommendations and documents framing the 
database. Together with the ethics research group, the Committee carried out evaluations in 
the existing national-level procedures with a dual objective: 1) to elaborate a core charter 
rules governing data-sharing within the database, and 2) to harmonize information and 
consent documents.  
The work was performed as a co-construction between health professionals, ethics experts, 
and patient representatives relaying patient expectations. The standpoints and expectations of 
patients and families were also concurrently investigated via a survey led with French 
families participating in the annual meeting of the European Leukodystrophies Association 
(ELA), where 55 questionnaires were returned and analyzed (unpublished results). This 
approach resulted in the production of a charter defining the binding commitments and 
responsibilities of health professionals in terms of the preservation, use and sharing of 
participants’ data. Based on international texts and recommendations issued by international 
organizations,[6-10], the charter develops the main principles on data privacy, regulation of 
potential value and the exploitation of data, as well as issues tied to consent, information and 
release of results. The charter anchors transparency as a core functional requirement and an 
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essential tool for answering patients/families’ questions on individual elements included in 
information and consent documents. Indeed, McCormack et al highlighted that a particular 
concern and possible source of anxiety for patients and families is ownership of the 
registry/database and the data contained, as it defines who controls how the data is used,[11]. 
The charter is accessible on the dedicated LeukoTreat website 
(http://www.leukotreat.eu/leukodatabase-ethics.php).  
 
DATA SHARING IN LEUKODB 
The primary concern of the LEC was to establish ethical rules governing the sharing of data. 
The database gathers sociodemographic and medical data extracted from patient records, 
including biological, radiological, electrophysiological data, genetic studies and cognitive 
evaluations. The data is collected and processed in LeukoDB by the referent Clinical Centers 
in charge of the patients. In the context of biomedical research, the aim of building a 
European database is to gather data for the largest number of patients in order to optimize: 
- epidemiogical knowledge on the various forms of the disease, 
- genotype–phenotype correlation, 
- knowledge of the natural history and evolution of these diseases,  
- the development of  therapeutic approaches and recruitment in future clinical trials.  
Ethical principles are defined in LeukoTreat to ensure that each participating entity in the 
different countries has obtained approval from their local data protection and ethics 
authorities and guarantees the same level of data protection and security, in accordance with 
Directive 95/46/EC of the European Parliament and of the Council of 24 October 1995,[6] on 
the protection of individuals with regard to the processing of personal data.  Confidentiality is 
ensured in accordance with the right to privacy of life, as defined by the Convention for the 
Protection of Human Rights and Dignity of the Human Being with regard to the Application 
of Biology and Medicine,[7]. In LeukoDB, data is secured and cannot be used to stigmatize 
and/or discriminate the people concerned, in accordance with the International Declaration on 
Human Genetic Data,[10]. Data for research purposes is coded and rendered anonymous for 
researchers, i.e. it is impossible to identify an individual participant. Only the physicians in 
charge of the patients can combine clinical data with personal data. The data is accessible to 
researchers engaged in the LeukoTreat program. For researchers not engaged through the 
LeukoTreat agreement, access is provided through a specific request procedure. Publications 
on the basis of the data will always be anonymous. 
Finally, participants have the right to access their personal data, in compliance with Directive 
95/46/EC of the European Parliament and of the Council of 24 October 1995 on the 
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protection of individuals with regard to the processing of personal data,[6]. LeukoTreat 
members and partners are committed to respect these principles, as listed in the leukoDB 
charter, and must include them in the informed consent for participants.  
 
 
SPECIFIC ETHICAL ISSUES IDENTIFIED  
A lack of frontier between care and research: what impact? 
The ethical framework governing biomedical research revolves around the dichotomy 
between care and research. However, in rare diseases like LDs, research and care are very 
often intertwined, as diagnostics or therapies are often only available at the research stage. 
Furthermore, the sense of urgency in diseases with no effective therapies is particularly  
conducive to therapeutic misconception,[12]. With the focus on implementing the European 
database on LDs in LeukoTreat (LeukoDB), the lack of a clear distinction between care and 
research has been a recurrent subject of discussions within the LEC.  
The database is partly built from clinical data collected from patients as they present for care. 
It was thus recognized that confusion could occur for a number of patients/families being 
unaware that their medical data was being shared for research purposes, even though they had 
signed a consent form for this purpose. In practice, the only approach available to the patient 
or to his/her representative is to give consent for his/her medical information to be used for 
research purposes. Furthermore, medical acts such as lumbar puncture, blood tests or MRI can 
be realized at the same time for both care and/or research goals. The upshot is a risk of 
trivializing certain research procedures for clinicians and researchers ― procedures that 
patients would then perceive and experience as acts of care. If the information given to 
patients does not make a clear distinction between the processes of care and research, then 
patients may find themselves in a situation where consent is not fully informed. 
The LEC thus responded by addressing two main issues. First, what does it mean for a patient 
to participate in a database? Second, what do information and consent mean in this context?  
Patient conceptions of biomedical research usually revolve around technical and drug trials 
involving interventions on human beings. The LEC and the research group both felt that the 
fact that patients’ data would be used for research was an important message to deliver. 
Indeed, there was the feeling that patients did not have a clear enough perception about the 
need to be informed and protected in this kind of research that they do not consider research 
as there is no intervention on the human body. Care professionals reported that patients’ main 
fear is that samples might be taken without being justifiable within a strict ‘care’ framework. 
The LEC thus concluded on the importance of communication to patients on all the aspects 
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and facets involved in the protection of human subjects in this kind of research.  
 
Participation in the database: what information? 
The challenge is to ensure that registry/database participants receive adequate information to 
make an informed decision. Participation in a database or a registry is somewhat different 
from participation in clinical trials. However, the LEC stressed the importance of obtaining 
individuals’ consent to use their health information for research purposes as a fundamental 
ethical consideration as regard to the principle of respect for persons participating in registries 
and databases,[1, 13, 14]. Debate as to what the consent process should be and what 
information content should be delivered is an ongoing process, as it depends on the context in 
which data and specimens (or links to specimens) is collected, stored and used,[15-17]. The 
LEC held dedicated meetings addressing the ethical issues encountered in the LeukodB 
setting. Aside from well-established principles such as information on scientific goals, 
privacy and security, and rights to access, rectify and delete personal data, the LEC also made 
a number of specific recommendations as described below and presented in Table 1. These 
recommendations are made available to all database participants (patients and families) via 
the project website.  
 
Table 1. Specific points considered by the LEC for patient participation in the database 
(LeukoDB)  Information should help make the distinction between care and research  Need for a charter establishing the binding commitments of health professionals   At the time of consent, information should specify: 
- the nature and origin of data collected (‘genetic’ information should be specified) 
- the conditions for datasharing, and the existence of a charter 
- data preservation continuing post-mortem    Age and mental ability should be taken into consideration by establishing different 
models of consent.  After inclusion, ongoing information should be delivered: 
- regularly, on an annual basis, 
- including non-results information on the database and aggregated research results.  Individual results should only be delivered by physicians, and only once the merits 
have been weighed up. 
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Data description 
The patient should be informed that data are derived from all elements included in his/her 
medical file and that biospecimens issued for care may be used for research, although specific 
consent is requested before taking each different kind of sample. A clear description of the 
data collected and shared within the database should be provided. For example, LeukoDB 
includes clinical data (the Leukoclinical database), mutation data (the Leukomutation 
database), and a listing of existing biospecimens most often collected during care. The 
database collates personal, socio-demographic, psychological, and familial history elements 
derived from consultation and from everyday life, plus biological and medical imaging data.  
 
Length of data conservation 
For public health and scientific research interests, long-term data preservation is crucial, 
especially in rare diseases where data are scarce, heterogeneous, and take a long time to 
collect,[13, 14]. Each patient’s data is precious information for studying the natural history of 
the disease and for research. Thus, patients should be informed about the interest of being 
able to conserve data with no limits on time. The LEC has integrated this key data 
conservation concern, as the choice was made for LeukoDB to keep data even after the 
participant’s death, except if an opposite choice was expressed during the patient’s lifetime. 
In this case, the irreversible anonymization of the data already collected and stored is 
considered.  Although patient representatives participating in the LEC agreed on these points, 
they underlined that families and patients may have other wishes during their lifetime. Thus, 
the recommendation was that these questions should be clearly stated to patients/families at 
the time of consent in order to allow them to express potential opposition. 
 
Adapting information to patients’ clinical situations 
Given that a major percentage of LD patients are either minors and/or cognitively-impaired 
individuals, the LEC stated the necessity to adapt information on a case-by-case basis. EU 
regulations on minors or incapacitated adults unable to give legal informed consent require 
that all persons are given information geared to his/her capacity of understand it,[18], but 
there still appears to be room for improvement in the delivery of written information in 
pediatric research,[19]. The LEC established recommendations in terms of personalized 
information and template documents, but insisted on the fact that clinicians in reference 
centers should take ownership of these documents and adapt them to the individual situations 
they encounter. Recommendations were made to improve the involvement of children in 
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health research,[20]. Documents should be re-drafted in a simplified language, and drawings 
or cartoons may prove helpful for supporting the information given by the medical team and 
parents alike. Such a document for children illustrating the participation to the LeukoDB was 
produced in the form of a storyboard (available on the LeukoTreat website). For patients with 
partial mental impairment, the LEC proposed the development of simplified materials to 
complement the document submitted to the legal representative. In addition, the LEC 
recommended that in all cases, oral information should be delivered adapted to the patient’s 
profile. 
Having the adolescent and their parents counter-sign consent is often considered an option. 
Furthermore, the LEC recommended that once when the minor becomes adult, they should be 
given the occasion to reconsider research participation, after first receiving exhaustive 
information.  
 
Patients already included in national databases 
The gathering of data at pan-European level raises the question of information for patients 
already included in the national databases. Is the initial consent signed for inclusion in 
national databases still valid for the transition to the pan-European database? The LEC 
proposed to examine existing information sheets and consent forms at national level. It was 
decided that if those were conform to the requirement criteria established by the LEC, then 
there was no need to have the participants sign a fresh consent. However, if the gap between 
the initial documents and the recommendations is judged too wide, a procedure should be 
launched to seek new informed consent. For the three countries responsible for starting the 
inclusions, i.e. Germany, Italy and France, the LEC arbitrated to validate that the initial 
consents were consistent with the new criteria. Two recommendations were made by the 
LEC: first, every patient included in the future should sign a harmonized consent according to 
the model established, and second, patients having signed initial consents should benefit from 
information about the evolution of the national databases enabling them to give properly-
informed ongoing consent.  
 
Ongoing information 
For the autonomy principle to be effective and for participants to be able to continue their 
participation, they need to have access to information after the time of inclusion. It is logical 
to expect new elements to emerge over time, whether at the organizational, scientific or 
human level. Indeed, this is a condition for ongoing consent,[21], and is particularly important 
in long-term studies, as we previously emphasized for HIV cohort participants,[22].  
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Note that follow-up information also offers an opportunity to get patients involved in research 
and create partnerships with health professionals, as well as to increase the sense of 
community surrounding their disease. Patient registries and databases are of great importance 
to rare disease patients and patient organizations who are actively engaged and involved in 
their setting and development,[23].  
Finally, giving ongoing information also offers a framework to respect the fundamental right 
of participants to withdraw from research at any time.  
Thus, the LEC’s recommendation was that all research shareholders, clinician–researchers, 
health professionals and patient organizations should collaborate on delivering regular 
information bulletins, at least one a year, via a newsletter released in paper-print and online at 
the dedicated LeukoTreat website and on patient organization websites. Printed documents 
are essential as they are the primary medium for communication in the reference centers, 
where the information content can be explained and expanded upon if necessary.  
As to the content of ongoing information, the LEC stressed the importance of delivering 
general information on the database, its evolution (number of patients included, evolution of 
participation in different countries and centers, etc.), the scientific project developed, and any 
new orientations adopted ― all of which is deemed ‘non-results information’,[24]. The 
newsletter should also integrate aggregated research results, once validated and written in an 
accessible form, with the whole process relying on the interaction with patient organizations. 
As concerns individual research results, the recommendation in Leukotreat was that they 
should only be communicated in a clinical perspective, leaving it to the physician to decide 
whether it was relevant to communicate them and whether the patient was ready and/or able 
to discuss their significance results and the potential incidence on their care,[25–27].  
 
EXPERIENCES IN OTHER CONSORTIA 
Registries and databases gathering trans-national patient data are recognized as high priority 
tools in the field of rare diseases. However, their regulation is considered to be in its early 
stages in most European countries where legal requirements are not always the same,[23]. 
Most publications reporting on database management tend to focus on technical aspects, the 
way data is collected, data quality and use. The way ethical aspects tied to patients’ rights and 
information are handled is rarely described in detail, even though some projects make ethical 
documents publicly available on their websites. This is the case for the database for primary 
immunodeficiencies developed by the European Society for Immunodeficiencies (ESID),[28]. 
The documents describe how to enter and access patient data in a secure decentralized way, 
the need for documenting centres to obtain permission from local data protection and ethics 
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authorities, and the duty to conform to European Directive 95/46/EC[6]. Patients are informed 
that data is shared between different centres and may be used for research purposes. 
Documenting centres must obtain patient informed consent before entering data. Models of 
patient consent forms are also available on their website. a paper by Holland et al,[29] on the 
Prader-Willi database describes the database objectives and organization scheme and 
underlines the need for ethical management and follow-up. The paper also stresses the 
importance of this kind of database for many researchers, thus implying the need to decide 
who owns the data, who has access, and for what research purposes. Bergin et al,[30] on the 
EpiNet epilepsy database, which gathers data from thirteen countries, points to how data 
transmission is regulated in other countries. Approval was granted by the relevant authorities 
in all thirteen countries from which data were transmitted, and in all cases the ethics 
committees and institutional review boards were satisfied that patient information was secure 
and confidential, that the encryption processes used in the transmission of the information 
were adequate, and that transmission of the data was justified.  
The LeukoTreat project also relies on the principle of ethical approval by national committees 
but goes further to insist on the necessity to harmonize practices as far is is practicable and to 
harmonize the content of patient information collected in different countries for participation 
in the database. To achieve this objective, an ethics steering committee (the LEC) was 
adjoined to the project. This was considered an added value in terms of database management 
. For the LEC, it is important that participants in national databases are informed of the 
existence and purpose of data sharing between European countries and of the conditions 
under which data is shared and secured. We recommend that all these information items be 
made available on a public-access website. Emulating the European muscular Treat NMD 
network,[31], LeukoDB describes the responsibilities and engagements of the different 
stakeholders in a publicly available charter. We also propose reflexion on the provision of 
continuous information to participants to keep them up-to-date on the evolution of the 
database, the orientations of the research performed, and its results. 
 
CONCLUSION  
This paper reports on experience shared by healthcare professionals, ethics experts and patient 
representatives on ethical issues management in the setting of a European database on 
leukodystrophies. The LeukoTreat Ethics Committee established at the outset of the 3-year 
project acted as a forum for optimizing ethical procedures geared to the rights and 
expectations of participants.  
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In this context of a database on rare diseases, patients and families are most often committed 
by conviction, leading to a strong participation, especially as the risks linked to participation 
appear low. However, as data are often derived from medical records, participants may be 
unaware that their data is being used for research purposes.  
Given that therapies are mostly inexistent at the present time, research progress harbors great 
expectations, which means the information process must be thought out as a long-term 
process. The right to be informed after the initial time of consent (ongoing consent) is a key 
element, as participants may duly expect feedback. Ongoing feedback on the database, 
including delivering global results in a broad-audience format, thus emerged as a key 
recommendation. The delivering of information should be built on a partnership with patient 
organizations. This information should be made available to all patients in the partner 
countries developing the database and should be scaled to different patient’s profiles.  
The LEC recommendations help better organize and structure the information to be delivered, 
and to optimize the scientist–patient partnership that helps build efficient databases. 
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